Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Galinpepimut-S in Acute myeloid leukemia (AML). The expected timing is based on the latest available company guidance and may change.
08/11/26:- REGAL Ph3 nearing 80th event. Final analysis follows database lock and unblinding.
Verification
Confirm timing and program details against the company announcement or filing.